- Trials with a EudraCT protocol (524)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
524 result(s) found for: Respiratory Tract Diseases AND Asthma.
Displaying page 20 of 27.
| EudraCT Number: 2019-003082-17 | Sponsor Protocol Number: 3103017 | Start Date*: 2020-07-22 |
| Sponsor Name:Orion Corporation Orion Pharma | ||
| Full Title: EFFECT OF ELECTRONIC MONITORING AND FEEDBACK ON ADHERENCE TO EASYHALER CONTROLLER MEDICATION IN PATIENTS WITH ASTHMA | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-003242-16 | Sponsor Protocol Number: MRx-4DP0004-I-001 | Start Date*: 2019-04-09 | |||||||||||
| Sponsor Name:4D pharma plc | |||||||||||||
| Full Title: A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx-4DP0004, (a lyophilised formulation of Bif... | |||||||||||||
| Medical condition: Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002977-27 | Sponsor Protocol Number: BECRO/RESP/AERO-PD | Start Date*: 2023-01-23 | ||||||||||||||||
| Sponsor Name:Respirent Pharmaceuticals Co. Ltd | ||||||||||||||||||
| Full Title: A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respiren... | ||||||||||||||||||
| Medical condition: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness ... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-002208-37 | Sponsor Protocol Number: HVH237CIMM-COVID19 | Start Date*: 2021-04-29 | |||||||||||
| Sponsor Name:Respiratory Research Unit 237, Hvidovre Hospital | |||||||||||||
| Full Title: The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare util... | |||||||||||||
| Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001868-19 | Sponsor Protocol Number: 2015-001 | Start Date*: 2015-10-15 | |||||||||||
| Sponsor Name:University medical center of Johannes Gutenberg University Mainz | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study | |||||||||||||
| Medical condition: severe eosinophilic asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-003004-33 | Sponsor Protocol Number: AR-DEX-22-01 | Start Date*: 2023-04-26 | |||||||||||
| Sponsor Name:Areteia Therapeutics, Inc. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe ... | |||||||||||||
| Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-002666-76 | Sponsor Protocol Number: 200363 | Start Date*: 2015-06-17 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma | |||||||||||||
| Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-019466-81 | Sponsor Protocol Number: LPA114255 | Start Date*: 2016-12-12 |
| Sponsor Name:GlaxoSmithKline Research & Development | ||
| Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100 mg, GSK2190915 300 mg... | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004882-10 | Sponsor Protocol Number: SAS110099 | Start Date*: 2016-08-03 |
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
| Full Title: A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001833-26 | Sponsor Protocol Number: OC000459/019/15 | Start Date*: 2015-07-21 | |||||||||||
| Sponsor Name:Atopix Therapeutics Ltd., | |||||||||||||
| Full Title: THE EFFECT OF OC000459 ON EOSINOPHILIC AIRWAY INFLAMMATION AND ASTHMA CONTROL IN SUBJECTS WITH REFRACTORY EOSINOPHILIC ASTHMA: A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL | |||||||||||||
| Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-005293-22 | Sponsor Protocol Number: D589GC00003 | Start Date*: 2014-08-06 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80... | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: SK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-002722-23 | Sponsor Protocol Number: NL44755.044.13 | Start Date*: 2013-07-09 |
| Sponsor Name:Medisch Spectrum Twente | ||
| Full Title: The protective effect of a single dose inhaled steroid with different body postures against exercise induced bronchoconstriction | ||
| Medical condition: Exercise Induced Bronchoconstriction | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-024006-35 | Sponsor Protocol Number: C38072/3083 | Start Date*: 2011-05-05 | |||||||||||
| Sponsor Name:Teva Branded Pharmaceutical Products, R&D, Inc. | |||||||||||||
| Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75... | |||||||||||||
| Medical condition: Treatment for patients with eosinophilic asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) DE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000583-30 | Sponsor Protocol Number: CBP-201-WW002 | Start Date*: 2021-12-21 |
| Sponsor Name:Suzhou Connect Biopharmaceuticals Ltd. | ||
| Full Title: A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients with Moderate to Severe Persistent Asthma with Type 2 Inflammation. | ||
| Medical condition: Moderate to Severe Persistent Asthma with Type 2 Inflammation | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: PL (Completed) HU (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-005054-36 | Sponsor Protocol Number: MK-1029-015 | Start Date*: 2016-08-22 |
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | ||
| Full Title: A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects with Persistent Asthma That is Uncontrolled While Receiving M... | ||
| Medical condition: Persistent asthma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: PL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-003005-30 | Sponsor Protocol Number: AR-DEX-22-03 | Start Date*: 2023-06-28 | |||||||||||
| Sponsor Name:Areteia Therapeutics, Inc. | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinop... | |||||||||||||
| Medical condition: Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-003303-14 | Sponsor Protocol Number: DETACT | Start Date*: 2023-02-16 |
| Sponsor Name:Medical University of Vienna | ||
| Full Title: Effect of Dupilumab on mucus plugs and inflammatory patterns in sEvere asThmatiC paTients (DETACT) | ||
| Medical condition: Severe asthma is a chronic inflammatory condition of the airways, characterized with wheezing, breathlessness, chest tightness and coughing. T2-high asthma is promoted by differentiated T helper c... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002165-34 | Sponsor Protocol Number: RC19_0292 | Start Date*: 2020-12-03 | |||||||||||
| Sponsor Name:CHU of Nantes | |||||||||||||
| Full Title: Predictive Signature of Benralizumab Response | |||||||||||||
| Medical condition: Severe asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001529-30 | Sponsor Protocol Number: EDP938-102 | Start Date*: 2020-09-29 | |||||||||||
| Sponsor Name:Enanta Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection with Respiratory Syncytial Virus in Ambula... | |||||||||||||
| Medical condition: Respiratory syncytial virus (RSV) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) NL (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003397-27 | Sponsor Protocol Number: BDB-AS-301 | Start Date*: 2014-04-02 |
| Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||
| Full Title: A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered... | ||
| Medical condition: Persistent Asthma | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: HU (Completed) PL (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.